Pierre Beaurang is Chief Business Officer at Nurix Therapeutics, Inc. (NRIX). They have made 7 open-market trades across 1 company since 2021, most recently 2021-08-10.
CIK 0001817226
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
0 open-market purchases, against 7 sales. Too few scored purchases to measure a record yet.
| Ticker | Shares | Value |
|---|---|---|
| NRIX | 6,210 | $151K |
Shares reported on the most recent Form 4, priced at the 2021-08-11 close.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| NRIX | SELL | 2021-08-10 | 2021-08-11 | $29.86 | $448K | +6.8% | +17.3% | +8.6% |
| NRIX | SELL | 2021-07-12 | 2021-07-12 | $23.93 | $179K | +31.4% | +31.2% | +20.0% |
| NRIX | SELL | 2021-06-10 | 2021-06-11 | $29.37 | $220K | +1.9% | -17.2% | +27.0% |
| NRIX | SELL | 2021-05-10 | 2021-05-11 | $26.43 | $378K | -6.3% | +10.3% | +13.8% |
| NRIX | SELL | 2021-04-12 | 2021-04-13 | $27.23 | $394K | +15.4% | -5.0% | -9.8% |
| NRIX | SELL | 2021-03-08 | 2021-03-09 | $37.01 | $548K | -16.1% | -19.3% | -20.7% |
| NRIX | SELL | 2021-02-18 | 2021-02-22 | $35.24 | $782K | -15.8% | -26.5% | -37.2% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.